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Campylobacter infections pose an important public health problem in the Netherlands. 
Approximately 79,000 persons per year are estimated to experience symptoms of acute gastroenteritis. 
Further annually some 1400 ReA cases, 60 GBS cases and 11 IBD cases are associated with a 
previous Campylobacter infection. Using a stochastic simulation model the disease burden and the 
cost-of-illness of Campylobacter infections and its sequelae were estimated. Estimates of the 
Campylobacter-associated disease burden and costs-of-illness were 1185 DALYs (90% C.I. 693 – 
1845 DALYs) per year and some 21 million € (90% C.I. 10 - 38 million €) per year respectively. 
 






Campylobacter infections in humans cause acute gastro-enteritis (GE), which, in most cases, is 
self-limiting within a few days to weeks. For some patients the disease is fatal. Guillain-Barré 
Syndrome (GBS), reactive arthritis (ReA) and inflammatory bowel disease (IBD) are the most 
significant sequelae occurring occasionally after campylobacteriosis. Human Campylobacter 
infections pose an important public health problem in the Netherlands.  
With the availability of a more recent Dutch epidemiological study with a much lower estimated 
annual number of GE cases than in a study carried out in the earlier nineties, an update of the previous 
estimate of the disease burden associated with Campylobacter infections and sequelae in the 
Netherlands of Havelaar et al. (2000a, b) was necessary. This was the first objective of the current 
study. Given that there is no estimate of the cost-of-illness associated with Campylobacter infections 
and the consequences of its sequelae for the Dutch society, the second objective of this study was to 
estimate the cost-of-illness related to Campylobacter infections and its sequelae. 
 
 
2. Methodological  approach 
 
Using a stochastic simulation model we estimated the cost-of-illness and the disease burden 
associated with Campylobacter infections and sequelae. A previous disease burden estimate was updated using Disability Adjusted Life Years (DALY’s). We took into consideration each of the 
different health states associated with Campylobacter infection or its sequelae. For all four illnesses 
Dutch estimated disability weights were used (Stouthard et al., 1997). The estimated annual GE 
incidence was based on a recent conducted population study in the Netherlands by de Wit et al. 
(2001b). GE estimates for symptom length and symptom severity were based on Dutch and English 
studies (Anonymous, 2000c; de Wit et al., 2001a, b; van Pelt et al., 2003). Annual incidence, 
symptom length and symptom severity GBS estimates were based on Dutch studies only (Bernsen et 
al., 1997; van Koningsveld et al., 2000). Annual incidence, symptom length and symptom severity 
ReA estimates were based on a recent published Finish study (Hannu et al., 2002). The estimated 
annual incidence of Campylobacter-associated IBD cases was based on a lately conducted Danish 
population study (M. Helms, Serum State Institute, unpublished data). Symptom length and symptom 
severity IBD estimates were based on a published markov model analysis of a population-based 
cohort conducted in the States (Silverstein et al., 1999). 
Following the Dutch guidelines for human health care evaluation studies, we estimated the direct 
health care costs, direct non-health care costs and indirect non-health care costs associated with 
Campylobacter infection and its sequelae (Oostenbrink et al., 2000). Dutch cost estimates for the year 
2000 were used (Anonymous et al., 2000a, b; Oostenbrink et al., 2000). The direct health care costs 
considered included e.g. general practice (GP) consultations, hospitalization, drugs, rehabilitation and 
other medical services. Travel costs of patients and eventually co-payments by patients were 
considered as direct non-health care costs. Applying the friction cost method, we estimated the 
productivity losses (indirect non-health care costs) that occurred due to sickness leave of sick people 
and premature mortality, and in the case of GE, also of third persons taking care of sick persons. The 
friction cost method applies that production losses are only considered for the period that is needed to 
replace a sick, invalid or death worker, the so called friction period (Koopmanschap et al., 1995, 
1992). 
Estimates on medical services used for the different illnesses were based, wherever available, on 
Dutch studies and data (Bernsen et al., 2002, 2001; de Wit et al., 2001b; Prismant, 2003; van 
Koningsveld et al., 2000). In the case of ReA and IBD, we had to fall back on international published 
literature (Blomqvist et al., 1997; Hannu et al., 2002; Rösch et al., 2002a, b; and others). Despite all 
efforts made information on the use of medical services and on the length of sickness leave of ReA 
patients were scarce.  
  The estimated DALYs and cost-of-illness with regard to the different illnesses associated with 
Campylobacter infections are presented both discounted and not discounted. We hereby used the 
officially Dutch recommended discount rate for public sector investment, which is 4 %. (Oostenbrink 
et al., 2000). Applying a discount rate is generally used to account for the fact that e.g. health today is 
valued higher than health in the future, and for the fact that there is uncertainty about future 
possibilities to ‘better’ treat diseases. 
 
 
3.  Summarizing the main results 
 
Within this paper only the main results are shown. Details of the assumptions made in order to 
estimate the incidence, the disease burden and the cost-of-illness for GE, ReA, GBS and IBD 
respectively, and a detailed description of the applied sensitivity analysis are available on request by 
the first author. We discuss in this paper only assumptions that have an important impact on our final 
outcomes.  
 
3.1  Estimated incidences of Campylobacter infections and associated sequelae.  
 
The estimated annual incidence of GE cases in the Netherlands, with a population of 16 million, 
was estimated to be on average 79,000 cases with a 90% confidence interval (C.I.) of 28,000 to 
162,000 GE cases (table I). In nearly 30 cases is GE fatal (90% C.I.: 13-47). For some of the GE 
patients the Campylobacter infections resulted in sequelae, such as ReA, GBS or IBD. The annual incidence of GE cases was by far larger than the estimated average 1400 ReA cases, the estimated 
average 59 GBS cases, whereof 2 fatal GBS cases and the estimated average 11 IBD cases (table I.). 
Therefore most cases of Campylobacter infections in humans would result only in GE. Complications 
such as ReA, GBS or IBD, respectively, or fatal GE and fatal GBS cases after a Campylobacter 
infections are relative rare. Of all sequelae related to previous Campylobacter infections, ReA is by 
far the most occurring sequelae.  
 
 
Table I. The estimated mean, 5
th, 50
th and 95
th percentile of annual incidences of Campylobacter-
associated GE cases, ReA cases, GBS cases, IBD cases, fatal GE cases and fatal GBS cases 
respectively, in the Netherlands. 
  Estimated annual incidence 
 5%  Mean  50%  95% 
Morbidity        
C. associated GE cases  28,000  79,000  69,000  162,000 
C. associated ReA cases  440  1,400  1,200  3,100 
C. associated GBS cases  29  59  58  98 
C. associated IBD cases  5  11  11  20 
Mortality        
C. associated fatal GE cases  13  28  27  47 
C. associated fatal GBS cases  0  2  2  6 
 
 
3.2  Estimated disease burden due to Campylobacter infections and associated sequelae.  
The estimated disease burden associated with Campylobacter infections and sequelae for the 
Dutch society was considerable, on average 1185 DALYs with a 90% C.I. of 693 DALYs to 1845 
DALYs (table II). More than 50% of the estimated mean disease burden associated with 
Campylobacter infections and sequelae in the Netherlands is due to GE cases. About 25% is due to 
GBS cases and 11% is due to both IBD and ReA cases (figure I.). More than a third of the total 
estimated mean disease burden is due to YLL (figure II.). By discounting the disease burden with 4%, 
YLL accounts still for nearly a third of the total estimated disease burden.  
 
 
Table II. Mean, 5
th and 95
th percentile of the estimated disease burden due to Campylobacter-
associated GE cases, GBS cases, ReA cases, IBD cases and the sum of all illness cases, respectively 
in the Netherlands (year 2000). 
Disease burden  Description 
Not discounted  Discounted (4%) 
 5%  Mean  95%  5%  Mean  95% 
Disability adjusted life years (DALYs) 
C.-associated GE  294  635  1107  239  499  873 
C.-associated GBS  129  298  535  77  169  291 
C.-associated ReA  40  126  279  40  126  279 
C.-associated IBD  50  127  230  23  55  99 










Figure I. Distribution of the estimated average annual disease burden related to Campylobacter 



























YLD (4%) YLL (4%)
Figure II. Mean, 5
th and 95
th percentile of the estimated YLD and YLL respectively, due to 
Campylobacter-infections and sequelae in the Netherlands (year 2000). 
 
 
By dividing the average estimated DALYs by the average estimated annual incidence, we obtain 
an estimate of the ‘average’ DALYs/case. Chronic and long-lasting diseases, such as IBD and GBS, 
are responsible for higher disease burden per patient than short disease episodes, such as gastro-
enteritis. To provide with insight into the relative disease burden of all Campylobacter-associated 
diseases, we have summarized the estimated DALYs/1000 average cases for all four Campylobacter-
associated illnesses and the estimated DALYs associated with Campylobacter infections and sequelae 
per initial GE cases. Results are summarized in table III. 
 
Table III. Mean estimate of DALYs/1000 cases for average GE cases, GBS cases, ReA cases and IBD 
cases, respectively, all associated with Campylobacter infections (year 2000). 
  Not discounted DALYs/ 
1000 average cases 
DALYs due to GE/C. associated GE cases  8 
DALYs due to GBS/ C. associated GBS cases  5,000 
DALYs due to ReA/ C. associated ReA cases  90 
DALYs due to IBD/ C. associated IBD cases  11,600 
DALYs due to C.-infections and sequelae/C. associated GE cases  15 3.3  Estimated cost-of-illness due to Campylobacter infections and associated sequelae.  
 
The estimated cost-of-illness associated with Campylobacter infections and sequelae in the 
Netherlands for the year 2000 were with on average more than 20 million € (range 10 – 38 million € 
90 C.I.) considerable (table IV). Indirect non-health care costs accounted for nearly 2/3 of the 
estimated average total cost-of-illness, whereas direct health care costs accounted for approximately 
1/3. Direct non-health care costs were only of minor importance (table IV).  
Indirect non-health care costs, which were mainly productivity losses, accounted for 
approximately 90% of the total cost-of-illness related to GE cases. Whereas direct health care costs 
accounted for approximately 70% of the estimated cost-of-illness associated with IBD and GBS cases, 
respectively. The direct non-health care costs were only minor (less than 1% of total costs). The 
indirect non-health care costs related to GE cases is by far the greatest cost category in our estimated 
total cost-of-illness (figure III). Therefore it is not surprising that indirect non-health care costs 
accounted for approximately 2/3 of the estimated average total cost-of-illness.  
 
Table IV. Mean, 5
th, 50
th and 95
th Percentile of the estimated direct health care costs, direct non-health 
care costs, indirect non-health care costs and total costs respectively, all related to Campylobacter 
infections and sequelae for 2000 (undiscounted figures). 
Estimated costs (*1000 €) for the year 2000  Description 
5% Mean  50%  95% 
Direct health care costs  4,000  6,500  6,400  9,800 
Direct non-health care costs  16  51  49  122 
Indirect non-health care costs  5,200  14,000  12,600  29,400 
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Figure III. The mean estimated direct health care costs, direct non-health care costs and indirect non-
health care costs due to Campylobacter-associated GE cases, GBS cases, ReA cases and IBD cases 
respectively, for 2000 (undiscounted figures). 
 
 
For GE and ReA all costs were assumed to occur within the first year. In the case of GBS most 
costs would occur in the first years after disease onset and only for IBD, the associated cost-of-illness 
were assumed to be equally spread over the remaining life years of the patients after disease onset. 
Given that IBD cases accounts for ~10% of the total costs, discounting has, as shown in table V, only 
little impact on the estimated cost-of-illness related to Campylobacter infections and sequelae.  
Under the current assumptions, approximately 2/3 of the estimated mean cost-of-illness related to 
Campylobacter infections and sequelae in the Netherlands are made by GE cases, see figure IV. Of 
the estimated mean cost-of-illness about 17% were estimated to be made by GBS cases and 9% were estimated to be made by IBD cases. ReA cases accounted for only 1% of the estimated mean cost-of-
illness. However, in the current study the cost-of-illness related to ReA cases were probably 
underestimated.  
 
Table V. Mean, 5
th and 95
th percentile of the estimated cost-of-illness associated with Campylobacter 
infection and sequelae in the Netherlands, total and for each illness (year 2000). 
Estimated cost-of-illness (*10
6 €) for the year 2000  Description 
Not discounted  Discounted (4%) 
 5%  Mean  95%  5%  Mean  95% 
C. associated-GE  6.1  15.1  30.9  6.1  15.1  30.9 
C. associated-GBS  1.3  3.4  6.4  1.3  3.3  6.3 
C. associated-ReA  0.0
1 0.0
1 0.1  0.0
1 0.0
1 0.1 
C. associated-IBD  0.7  1.9  3.4  0.3  0.9  1.5 
Total costs  10.0  20.6  38.0  9.2  19.4  36.4 













Figure IV. Distribution of the estimated total cost-of-illness due to Campylobacter infections and 
sequelae into the different illnesses for the year 2000 (undiscounted figures). 
 
 
We further have summarized in table VI the estimated mean cost-of-illness per estimated GE 
case, GBS case, ReA case and IBD case, respectively, for the year 2000. For GE cases, we have 
considered the average costs due to GE only/GE case and the average costs due to GE and 
sequelae/GE case. The estimated costs per estimated ReA cases might be underestimated, as 
mentioned already earlier. Especially chronic and long-lasting diseases such as GBS and IBD resulted 
in high cost-of-illness per estimated case, opposite to e.g. the relative short GE episode/ average case. 
 
Table VI. Average estimate of cost-of-illness/ cases for an average Campylobacter-associated GE 
case, GBS case, ReA case and IBD case, respectively in the Netherlands for 2000 (undiscounted 
figures). 
 Average  cost-of-illness (€)/average case 
Costs due to GE/C.-associated GE case  190 
Costs due to GBS/C.-associated GBS case  58,000 
Costs due to ReA/C.-associated ReA case  20 
Costs due to IBD/C.-associated IBD case  173,000 
Costs due to GE & sequelae/C.-associated GE case  260 
 3.4  Sensitivity analysis  
 
Due to model uncertainties and the non-availability of some data, assumptions had to be made. 
With the help of sensitivity analyses the impact of such assumptions was analyzed. Details of the 
different assumptions and their impact on the results are available on request from the first author. In 
the following paragraph we only summarize those assumptions that had an important effect on our 
results. 
•  The assumed length of symptoms and the assumed sickness leave of GE cases not visiting a 
GP (approximately 2/3 of all GE cases) had a major impact on the assumed cost-of-illness. 
For example half a day longer (shorter) sickness leave/patient resulted in an increase 
(decrease) of the estimated total costs by more than 1 million €. Whereas the impact on the 
estimated disease burden was relative small. 
•  Given the large uncertainty of the population at risk to develop ReA after a Campylobacter 
infection, the assumed annual incidence of ReA cases had a major impact on the estimated 
disease burden. Assuming that on average 1400, 400 and 5,800 cases would develop ReA, 
resulted in an average estimated disease burden of 126, 38 and 520 DALYs respectively. 
•  More detailed knowledge about medicine use and sickness leave for ReA patients would 
probably result in a higher estimate of the cost-of-illness. But the total estimated costs due to 




4. Discussion   
 
The annual incidences of Campylobacter-associated GE cases, ReA cases, GBS cases and IBD 
cases in the Netherlands, with a population of 16 million, was estimated to be on average ~ 79,000, 
1400, 59 and 11 cases respectively. Most cases of Campylobacter infections in humans would result 
only in GE. Complications such as ReA, GBS or IBD, respectively, or fatal cases after a 
Campylobacter infections are relative rare. Of all sequelae related to previous Campylobacter 
infections, ReA is by far the most occurring sequelae, but in most cases also by far the less sever 
sequelae. Even if we would assume that only positive laboratory-confirmed Campylobacter infections 
could result in ReA, ReA would stay by far the most occurring sequelae after a previous 
Campylobacter infection.  
The estimated disease burden associated with Campylobacter infections and sequelae was with 
on average nearly 1200 DALYs slightly lower than the estimate of the previous Dutch disease burden 
study, which was on average 1400 DALYs. The estimated number of fatal GE cases and the estimated 
YLL are in both studies comparable. Disease burden due to non-fatal GE cases, ReA and GBS were in 
our study always slightly lower than in the earlier study. In the case of non-fatal GE cases, the 
difference was mainly due to the lower annual incidence assumed in our study. Consequently the 
annual ReA incidence was assumed to be lower as well. Although, we assumed the same annual GBS 
incidence, our estimate was slightly lower due to slightly elderly GBS patients. We used in our study 
another more representative dataset that included more patients from a larger geographic area.  
The greatest part of the estimated disease burden related to Campylobacter infections and 
sequelae was due to GE cases. But fatal GE cases, on average 30 cases, accounted for more than 1/3 
of the total estimated disease burden related to GE cases. Further it has to be notified that patients 
with chronic and long-lasting illnesses, such as IBD and GBS, had a larger impact on the estimated 
disease burden than the large amount of non-fatal GE cases. 
  The population at risk for developing ReA after a Campylobacter infection needs to be better 
defined in future research. Assuming that: a) all Campylobacter-associated GE cases visiting a GP 
(BASE) develop ReA; b) only positive laboratory-confirmed Campylobacter cases develop ReA; or c) 
all Campylobacter-associated GE cases might develop ReA, large differences in the estimated annual 
incidence of ReA cases were found. Consequently, also the estimated disease burden related to ReA 
varied a lot. With a better estimate of the ‘real’ number of ReA cases, it might be expected that also the estimated cost-of-illness varies enormously. Future research is needed in order to get a more 
reliable estimate of the population at risk. 
By applying the friction cost method, the estimated indirect non-health care costs related to 
chronic and/or long-lasting illnesses, and related to fatal cases, are by far lower than found in other 
studies. Former studies have used the human capital method, which is known for resulting in far 
higher estimates of productivity losses (potentially lost income as a consequence of disease 
considered). Apart from the considerable disease burden estimate, the estimated cost-of-illness 
associated with Campylobacter infections and sequelae were with on average more than 20 million € 
(range 10 – 38 million € 90 C.I.) also of importance. Therefore, when comparing our estimates with 
cost-of-illness estimates of other studies, differences in study methodology should be taken into 
account. 
Of the average estimated 20 million € total cost-of-illness, was the greatest part due to GE cases. 
Hereby played the productivity losses due to sickness leave of GE cases an important role. However, 
when comparing the estimated average costs per average case per illness, average IBD and average 
GBS patients were by far costlier to the Dutch society than for example GE patients. 
Given that productivity losses due to sickness leave of GE cases was one of the major costs of 
the total cost-of-illness related to Campylobacter infections and sequelae, better estimates of the 
length of sickness leave of especially GE patients not visiting a GP might help to improve the 
estimate. In case of for example half a day shorter sickness leave the estimate will have to be 
corrected downwards by more than 1 million €, whereas a longer sickness leave (+0.5 days) will raise 
the estimate of the cost-of-illness by more than 1 million €. Furthermore, newly available data, 
especially on ReA but also on additional aids and tools for GBS cases might help to improve the 
estimate of the cost-of-illness related to Campylobacter infections and sequelae. The latter cost 
component, however, will probably result in a higher estimate of the cost-of-illness than our estimate. 
Therefore, we regard the current estimate of the cost-of-illness related to Campylobacter infections 
and sequelae as an underestimation rather than an overestimation of the real costs. 
Despite all the shortcomings of this study, we could update the previous estimate on the disease 
burden related to Campylobacter infections and sequelae, whereby using new available data and 
knowledge. Further, this study is the first estimate of a cost-of-illness for the Dutch society 
considering not only Campylobacter-associated GE cases, but also associated sequelae. No earlier 
estimates of the cost-of-illness for the Dutch society associated with ReA, GBS and IBD were 
available. And although we considered in this study only the costs related to Campylobacter-
associated ReA, GBS and IBD cases, our results are a first step into estimating the cost-of-illness of 





The complex epidemiology of Campylobacter infections and sequelae and the limited available 
knowledge requires a well-balanced set of measure in order to prevent Campylobacter infections in 
humans effectively. With the goal to advise the Dutch government on the effectiveness and efficiency 
of measures aimed at reducing Campylobacter infections and sequelae in the Dutch population, the 
so-called CARMA (Campylobacter Risk Management and Assessment) project was launched.  
These CARMA project is mainly characterized by two key questions: 
1)  What are the most important routes by which the Dutch population is exposed to 
Campylobacter and can the contribution of these routes is quantified? 
2)  Which (sets of) measures can be taken to reduce the exposure to Campylobacter, what is their 
expected efficiency and societal support?  
For the Netherlands chicken meat was defined to be the major route of human Campylobacter 
infections, - approximately 40% of all human Campylobacter infections cases. Therefore within the 
CARMA project it was decided to focus in first instance on the chicken meat production chain. Next 
to a risk assessment an economic evaluation is needed in order to answer the second key question. 
Within the CARMA project an economic evaluation of different interventions in the chicken meat 
chain to reduce human Campylobacter infections will take place in the form of a cost-effectiveness 
analysis. The costs of the intervention applied in the chicken meat chain will be related to ‘reduced’ burden of disease and ‘reduced’ costs of illness. This will result in a cost-effectiveness ratio that 
should express the relative efficiency of several policy options to reduce the number of 
Campylobacter infections. As a first step in such an economic evaluation, the disease burden estimate 
and the cost-of-illness estimate associated with Campylobacter infections and sequelae is described in 
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